GENinCode (LON:GENI) Shares Down 20% – Should You Sell?

GENinCode Plc (LON:GENI)’s stock price dropped 20% during mid-day trading on Tuesday. The stock traded as low as GBX 0.64 and last traded at GBX 0.70. 22,954,143 shares were traded during trading, an increase of 346% from the average daily volume of 5,146,545 shares. The stock had previously closed at GBX 0.88.

GENinCode Stock Down 20.0%

The business has a 50 day simple moving average of GBX 0.88 and a 200 day simple moving average of GBX 0.99. The company has a debt-to-equity ratio of 117.74, a current ratio of 0.93 and a quick ratio of 15.88. The stock has a market cap of £5.27 million, a PE ratio of -0.34 and a beta of 0.59.

GENinCode (LON:GENI) last issued its earnings results on Tuesday, September 29th. The company reported GBX (0.38) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%. On average, equities research analysts forecast that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.